Stock Track | RECBIO-B Plunges 25% Intraday After Reporting Widening Annual Loss

Stock Track03-25

RECBIO-B's stock price plummeted 25% during intraday trading on Wednesday, following the release of the company's annual financial results for 2025.

The biopharmaceutical company reported a loss attributable to shareholders of 610 million yuan, representing an 8.54% increase compared to the previous year. While the company generated its first revenue of 12.7 million yuan after reporting nil revenue in 2024, the significantly widening loss appears to have disappointed investors.

RECBIO-B's loss per share came in at 1.15 yuan. The company highlighted its portfolio of more than 10 vaccine candidates, including strategic products like its novel adjuvant recombinant shingles vaccine and recombinant nine-valent HPV vaccine, but the substantial annual loss overshadowed these development updates in today's trading session.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1197825380?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-25 16:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1197825380","market":"hk","top_or_hot":-1,"title":"Stock Track | RECBIO-B Plunges 25% Intraday After Reporting Widening Annual Loss","media":"Stock Track","content":"<p>RECBIO-B's stock price plummeted 25% during intraday trading on Wednesday, following the release of the company's annual financial results for 2025.</p><p>The biopharmaceutical company reported a loss attributable to shareholders of 610 million yuan, representing an 8.54% increase compared to the previous year. While the company generated its first revenue of 12.7 million yuan after reporting nil revenue in 2024, the significantly widening loss appears to have disappointed investors.</p><p>RECBIO-B's loss per share came in at 1.15 yuan. The company highlighted its portfolio of more than 10 vaccine candidates, including strategic products like its novel adjuvant recombinant shingles vaccine and recombinant nine-valent HPV vaccine, but the substantial annual loss overshadowed these development updates in today's trading session.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | RECBIO-B Plunges 25% Intraday After Reporting Widening Annual Loss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | RECBIO-B Plunges 25% Intraday After Reporting Widening Annual Loss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-25 16:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>RECBIO-B's stock price plummeted 25% during intraday trading on Wednesday, following the release of the company's annual financial results for 2025.</p><p>The biopharmaceutical company reported a loss attributable to shareholders of 610 million yuan, representing an 8.54% increase compared to the previous year. While the company generated its first revenue of 12.7 million yuan after reporting nil revenue in 2024, the significantly widening loss appears to have disappointed investors.</p><p>RECBIO-B's loss per share came in at 1.15 yuan. The company highlighted its portfolio of more than 10 vaccine candidates, including strategic products like its novel adjuvant recombinant shingles vaccine and recombinant nine-valent HPV vaccine, but the substantial annual loss overshadowed these development updates in today's trading session.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02179","symbol_name":"瑞科生物-B","start_time":0,"source_url":"","article_id":"1197825380","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1197825380","pubTimestamp":1774425673,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"RECBIO-B's stock price plummeted 25% during intraday trading on Wednesday, following the release of the company's annual financial results for 2025.The biopharmaceutical company reported a loss...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02179":"瑞科生物-B"},"translate_title":"个股追踪|RECBIO-B盘中暴跌25%，此前公布年度亏损扩大","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02179":1},"content_text":"RECBIO-B's stock price plummeted 25% during intraday trading on Wednesday, following the release of the company's annual financial results for 2025.The biopharmaceutical company reported a loss attributable to shareholders of 610 million yuan, representing an 8.54% increase compared to the previous year. While the company generated its first revenue of 12.7 million yuan after reporting nil revenue in 2024, the significantly widening loss appears to have disappointed investors.RECBIO-B's loss per share came in at 1.15 yuan. The company highlighted its portfolio of more than 10 vaccine candidates, including strategic products like its novel adjuvant recombinant shingles vaccine and recombinant nine-valent HPV vaccine, but the substantial annual loss overshadowed these development updates in today's trading session.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1197825380","isCrawlerRequest":true}